Early adenotonsillectomy increases clinically-meaningful benefit compared to watchful waiting in children with mild sleep-disordered breathing
In a secondary analysis of the PATS randomized trial, 65% of children who received early adenotonsillectomy (eAT) experienced clinically-meaningful improvement on at least 2 of 4 domains (behavior, quality of life, subjective sleepiness, blood pressure) versus 39% in the watchful waiting group (p<0.01). A high Mallampati score (III or IV) was the only predictor of benefit (OR 4.16, 95% CI [1.22, 15.6], p=0.027).
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Early adenotonsillectomy increases clinically-meaningful benefit compared to watchful waiting in children with mild sleep-disordered breathing The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Early adenotonsillectomy increases clinically-meaningful benefit compared to watchful waiting in children with mild sleep-disordered breathing
This conclusion is most relevant to: Children aged 3.0-12.9 years with mild sleep-disordered breathing (snoring but little or no obstructive sleep apnea); mean age 6.6 years, 55% >5 years, 51% male.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Adenotonsillectomy for Children with Mild Sleep-Disordered Breathing: Who Benefits? (Sleep, 2026) —
How It Works
The proposed biological pathway:
- ▸Adenotonsillectomy removes enlarged tonsils and adenoids
- ▸Reduces upper airway obstruction during sleep
- ▸Improves ventilation and sleep quality
- ▸Result: Clinically-meaningful improvements in behavior, quality of life, sleepiness, and blood pressure
Who Might Benefit
Evidence fit by population:
- ▸Children aged 3.0-12.9 years with mild sleep-disordered breathing (snoring but little or no obstructive sleep apnea); mean age 6.6 years, 55% >5 years, 51% male
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Secondary analysis of a randomized trial, not a primary outcome
- ▸Only one predictor (Mallampati score) identified, limiting clinical utility for patient selection
Frequently Asked Questions
What is the definition of clinically-meaningful benefit in this study?▼
Clinically-meaningful benefit was defined as a composite outcome of clinically-significant change in at least 2 of 4 domains: behavior, quality of life, subjective sleepiness, and blood pressure.
What is a Mallampati score and why is it relevant?▼
The Mallampati score is a visual assessment of oropharyngeal size; a high score (III or IV) indicates a relatively small airway. In this study, it was the only baseline feature that predicted which children would benefit from adenotonsillectomy.
How many children benefited from early adenotonsillectomy compared to watchful waiting?▼
65% of children in the early adenotonsillectomy group experienced clinically-meaningful improvement, compared to 39% in the watchful waiting group (p<0.01).
Does this study support routine adenotonsillectomy for all children with mild sleep-disordered breathing?▼
No, the study found that most clinical features did not predict benefit, except for a high Mallampati score. This suggests that patient selection remains challenging and that not all children will benefit equally.
References
- 1.Chervin RD, Gueye-Ndiaye S, Cen M, Mitchell RB, Liu C, Ibrahim S, George A, Hjelm M, Kirkham EM, Baldassari CM, Wang R, Redline S, Rosen CL. “Adenotonsillectomy for Children with Mild Sleep-Disordered Breathing: Who Benefits?.” Sleep, 2026. PMID: 42421252 DOI: 10.1093/sleep/zsag169